Venus Remedies Limited (VRL) recognized for its in-house R&D excellence by the Department of Scientific and Industrial Research (DSIR)

Venus Remedies secures marketing authorisation for key cancer drugs from Philippines, Paraguay, Georgia and Moldova; strengthens global presence

Mumbai, May 16, 2023: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), one of India’s top 20 R&D spenders and a research-driven pharmaceutical company, proudly announced the renewal of recognition for its in-house Research and Development (R&D) unit by the Department of Scientific and Industrial Research (DSIR), Ministry of Science & Technology, Government of India. This renewal underscores Venus Remedies’ commitment to innovation, excellence in research, and its significant contributions to healthcare.

With 15 patented products brought to market and several others in the pipeline, VRL’s R&D portfolio demonstrates a progressive approach to drug development. Venus Remedies Limited has consistently invested in research and development. The company invested 3.53% of its total sales in R&D, from which it has generated 5.25% of its total revenue, which stood at Rs 575.18 crore in FY 2021-22. The R&D spend for the same period amounted to Rs. 20.31 crores.

“Our in-house R&D unit has been at the forefront of pioneering research and development initiatives,” said Mr. Saransh Chaudhary, CEO of Venus Medicine Research Centre and President of Global Critical Care at Venus Remedies. “This renewal of recognition from DSIR reinforces our position as a research-driven pharmaceutical company dedicated to bringing innovative and effective solutions to address global healthcare needs.”

Venus Remedies Limited (VRL) has emerged as a pioneer in developing innovative medical solutions to combat antibiotic resistance, a global health concern. As part of its commitment to addressing antimicrobial resistance, VRL has created a range of patented superbug-fighting solutions, including Elores. In recognition of its efforts to combat antimicrobial resistance, Venus Remedies Limited has become a member of the AMR Industry Alliance (AMRIA), joining over 100 globally renowned organizations in a coordinated response to this critical issue.

To support its cutting-edge research, Venus Remedies has acquired various pharmaceutical laboratory testing equipment, including HPLCs, kidney chip systems, UV spectrophotometers, incubators, biosafety cabinets, bioanalyzers, hematology analyzers, particle counters, and LC-MS among others.

Venus Medicine Research Centre (VMRC), the medicine research center of VRL in India, comprehensively focuses on solutions that can address health problems outspread worldwide. With Research & Development forming the foundation for all its endeavors, the primary emphasis is in the fields of Anti-Microbial Resistance (AMR), Oncology, Wound Care, and Pain Management. Venus Remedies Limited’s commitment to innovation extends to advanced drug delivery systems, targeted drug deliveries, molecular biology research, and integration of herbal medicine into its research, with a portfolio of several patented AYUSH medications.

The medical research center is well-equipped with Good Laboratory Practice (GLP) accredited labs to cater to unmet medical needs, innovative breakthroughs to advance healthcare solutions, and state-of-the-art capabilities to accomplish human cures. Besides the fundamental development & research it delves in, spreading healthcare awareness on critical subject matters, including the Anti-Microbial Resistance (AMR), remains a priority.

With the renewal of recognition from DSIR and its ongoing efforts to combat antimicrobial resistance, Venus Remedies Limited solidifies its position as a leading research-driven pharmaceutical company, dedicated to excellence in research and bringing innovative medical solutions to address global healthcare challenges.